公开(公告)号：EP3344245A1

公开(公告)日：2018-07-11

申请号：EP16763701.6

申请日：2016-09-01

申请人： AbbVie Inc.

发明人： GOSS, Sandra L. ,  KLEIN, Cheri E. ,  NG, Juki Wing-Keung ,  SALEM, Ahmed

IPC分类号： A61K31/4178 ,  A61K31/496 ,  A61K31/513 ,  A61K31/565 ,  A61P15/00

CPC分类号： A61K31/505 ,  A61K9/0053 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/513 ,  A61K31/565 ,  A61K31/567 ,  A61K2300/00

摘要： The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

公开(公告)号：EP3207162A4

公开(公告)日：2018-07-04

申请号：EP15851341

申请日：2015-10-14

申请人： UNIV PENNSYLVANIA

发明人： PATERSON YVONNE

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12Q1/68

CPC分类号： A61K39/0011 ,  A61K31/407 ,  A61K31/513 ,  A61K39/12 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/6037 ,  A61N5/10 ,  A61P35/00 ,  C12N7/00 ,  C12N2710/20034

摘要： The present invention provides methods of treating anal or vaginal tumors and cancers, comprising the step of administering to a subject a combination therapy comprising a chemo-radiation therapy and a recombinant Listeria strain.

公开(公告)号：EP3201174A4

公开(公告)日：2018-06-06

申请号：EP15847016

申请日：2015-10-02

申请人： THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV

发明人： WU JIAN HUI ,  TIAN XIAOHONG ,  LIU WEIGUO

IPC分类号： C07C275/40 ,  A61K31/17 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5375 ,  A61P35/00 ,  C07D209/08 ,  C07D213/75

CPC分类号： A61K31/17 ,  A61K31/192 ,  A61K31/277 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5375 ,  A61K45/06 ,  C07C275/24 ,  C07C275/30 ,  C07C275/34 ,  C07C275/40 ,  C07C275/42 ,  C07D209/08 ,  C07D213/75 ,  C07D215/38 ,  C07D233/64 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20 ,  C07D263/32 ,  C07D263/48 ,  C07D295/104 ,  C07D295/135 ,  C07D307/52 ,  C07D317/66 ,  C07D333/20 ,  C07D401/12 ,  C07D413/12 ,  A61K2300/00

摘要： Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the compounds are useful in the treatment of diseases or disorders that are AR negative.

公开(公告)号：EP2714031B1

公开(公告)日：2018-05-23

申请号：EP12738184.6

申请日：2012-05-30

申请人： Piramal Enterprises Limited

发明人： AGARWAL, Veena ,  BALAKRISHNAN, Arun ,  PERIYASAMY, Giridharan

IPC分类号： A61K31/337 ,  A61K31/4025 ,  A61K31/4412 ,  A61K31/513 ,  A61K31/517 ,  A61K33/24 ,  A61P35/00 ,  A61K39/395

CPC分类号： A61K31/4025 ,  A61K31/282 ,  A61K31/337 ,  A61K31/44 ,  A61K31/513 ,  A61K31/517 ,  A61K33/24 ,  A61K39/39558 ,  A61K2300/00

摘要： or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.

公开(公告)号：EP3191103A4

公开(公告)日：2018-05-16

申请号：EP15840602

申请日：2015-09-10

申请人： UNIV WASHINGTON

发明人： CORNELIUS LYNN ,  DEMEHRI SHADMEHR ,  KOPAN RAPHAEL

IPC分类号： A61K31/59 ,  A61K9/06 ,  A61K31/505 ,  A61K31/513 ,  A61K31/593 ,  A61K45/06 ,  A61P17/00 ,  A61P17/12 ,  C07D243/04

CPC分类号： A61K45/06 ,  A61K31/513 ,  A61K31/59 ,  A61K31/593 ,  A61K2300/00 ,  C07D243/04

摘要： The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.

公开(公告)号：EP3310357A1

公开(公告)日：2018-04-25

申请号：EP16730813.9

申请日：2016-06-16

申请人： H e x a l Aktiengesellschaft

发明人： KOHR, Thomas ,  WAWRA, Christian ,  MARCHESAN, Marco

IPC分类号： A61K31/4439 ,  A61K9/16

CPC分类号： A61K9/2866 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1682 ,  A61K31/155 ,  A61K31/4439 ,  A61K31/513 ,  A61K2300/00

摘要： The present invention belongs to the field of pharmaceutical industry and relates to a pharmaceutical composition comprising an intragranulate phase and an extragranulate phase, wherein the pharmaceutically active ingredient (API) 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile or a pharmaceutically acceptable salt thereof, is present in the intragranulate phase, wherein said intragranulate phase is free from microcrystalline cellulose. Further, the present invention relates to a process for preparing the same.

公开(公告)号：EP3307257A1

公开(公告)日：2018-04-18

申请号：EP16725108.1

申请日：2016-05-24

申请人： Friedrich-Alexander-Universität Erlangen-Nürnberg

发明人： BOSSERHOFF, Anja-Katrin ,  RIECHERS, Alexander ,  KÖNIG, Burkhard ,  BAUSE, Manuel ,  RAUSCHER, Fabian

IPC分类号： A61K31/138 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/425 ,  A61K31/426 ,  A61K31/435 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/517 ,  A61K31/53 ,  A61K31/5375 ,  A61P35/00

CPC分类号： A61K31/4184 ,  A61K9/0053 ,  A61K31/138 ,  A61K31/197 ,  A61K31/341 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/425 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/472 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/04

摘要： The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.

公开(公告)号：EP3307251A1

公开(公告)日：2018-04-18

申请号：EP16730210.8

申请日：2016-06-09

申请人： Rexahn Pharmaceuticals, Inc.

发明人： LEE, Young Bok ,  KIM, Deog Joong ,  PETERS, Godefridus J. ,  SARKISJAN, Dzjemma ,  MAZHARI, Reza

IPC分类号： A61K9/48 ,  A61K31/513 ,  A61K39/395 ,  C07D239/47 ,  A61P35/00

CPC分类号： A61K31/513 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2004 ,  A61K9/48 ,  A61K9/4841 ,  A61K39/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07D239/47 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/76 ,  C12Y207/01048 ,  G01N33/57496 ,  G01N2333/91215 ,  G01N2800/52 ,  A61K2300/00

摘要： or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.

公开(公告)号：EP3303294A1

公开(公告)日：2018-04-11

申请号：EP16736610.3

申请日：2016-05-25

申请人： Abbvie S.a.r.l. ,  Galapagos NV

发明人： ALTENBACH, Robert J. ,  COWART, Marlon D. ,  DE MUNCK, Tom Roger Lisette ,  DROPSIT MONTOVERT, Sebastien Jean Jacques Cedric ,  GFESSER, Gregory A. ,  KELGTERMANS, Hans ,  MARTINA, Sebastien Laurent Xavier ,  VAN DER PLAS, Steven Emiel ,  WANG, Xueqing

IPC分类号： C07D213/81 ,  A61K31/44 ,  A61P11/00

CPC分类号： C07D213/81 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D491/107

摘要： wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

公开(公告)号：EP3302454A1

公开(公告)日：2018-04-11

申请号：EP16734481.1

申请日：2016-05-25

申请人： Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA ,  Lusomedicamenta, S.A. ,  Laboratorio Medinfar-Produtos Farmacêuticos, S.A.

发明人： AFONSO, Nuno ,  SOUSA, Sara ,  VAZ, Rita ,  CHAPELA, Diana ,  CÔRTE-REAL, Sofia

IPC分类号： A61K31/12 ,  A61K31/138 ,  A61K31/198 ,  A61K31/513 ,  A61P25/16

CPC分类号： A61K31/137 ,  A61K31/12 ,  A61K31/138 ,  A61K31/198 ,  A61K31/513 ,  A61P25/16 ,  A61K2300/00

摘要： The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders. In particular, the invention relates to method of administering pharmaceutical compositions comprising effective amounts of tapentadol or a pharmaceutically acceptable salt or derivative thereof or, in other embodiments, stavudine or nabumetone, or a derivative thereof, for treating symptoms associated with Parkinson's disease, either as individual active agents, in combination with each other, or in combination with agents known to treat Parkinson's disease, such as the dopaminergic agent levodopa. The invention also relates to methods of preparing pharmaceutical compositions comprising effective amounts of tapentadol, stavudine, or nabumetone, or a derivative thereof, or further in combination with a dopaminergic agent, or derivative thereof, as well as to methods of using the pharmaceutical compositions in treating Parkinson's disease, related disorders, other conditions treated with dopaminergic agents, and other conditions with gait problems, for example by oral administration of the compositions.